Abstract library

286 results for "serotonin synthesis inhibitor".
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#870 Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Wim Meijer
Authors: Meijer W, Bruikman C, Beukeveld G, ...
#1068 Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Matthew Kulke
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease
Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Pablo Lapuerta
Authors: Lapuerta P, Kulke M H, Pavel M, Biran T, ...
Keywords: serotonin, 5-HIAA
#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome
Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Lowell Anthony
Keywords: serotonin, diarrhea
#1942 Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
Introduction: TELECAST assessed telotristat ethyl (TE), a tryptophan hydroxylase inhibitor, in patients (pts) with carcinoid syndrome (CS) with ≥1 CS symptom/sign and a mean 2.5 bowel movements (BMs) per day. Pts were somatostatin analog treated (89%), with gastrointestinal (90%; [diarrhea, 70%]) and cardiac disorders (42%), including carcinoid heart disease. At Week (W) 12, TE (250 and 500 mg 3×/day; tid) significantly reduced urinary 5-hydroxyindoleacetic acid (u5-HIAA) and BMs/day vs placebo (pbo) (p≤0.008). After W12, pts crossed over to an open-label extension (OLE) with TE 500 mg tid (W13–48).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel
Keywords: serotonin, safety
#2909 Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?
Introduction: Serotonin-secreting pancreatic neuroendocrine neoplasms (5-HT-secreting pNENs) are very rare. They are characterised by high urinary 5-hydroxyindole-acetic acid (5-HIAA) levels (or high serum 5-HT levels).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto